Dabrafenib Plus Trametinib Demonstrates Benefit in BRAF-Mutant Melanoma

Source: Targeted Oncology, June 2020

Axel Hauschild, MD, PhD, a professor of dermatology at the University Hospital Schleswig-Holstein, in Campus Kiel, Germany, discusses the key findings from the phase 3 COMBI-AD clinical trial, which demonstrated sustained long-term relapse-free survival benefit with the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) compared with placebo in patients with resected, stage III BRAF V600E/K-mutated melanoma.

In conclusion, we can say this is a highly effective treatment, says Hauschild. There is no doubt that for stage IIIA/B/C that this regimen will have benefit for patients.

One year of treatment with the combination of dabrafenib and trametinib is now considered the standard of care for this patient population, says Hauschild. This regimen is included in guidelines as the recommended treatment for patients with BRAF-mutant melanoma.

READ THE ORIGINAL FULL ARTICLE